PhD student in Bioethics & Health Policy at @JohnsHopkinsSPH @bermaninstitute | psychedelic ethics 🌱, research ethics
Joined March 2023
- Tweets435
- Following434
- Followers438
- Likes2K
Pinned Tweet
Working on getting a bibliography of sorts for psychedelic ethics/philosophy papers together - sharing in case it comes in useful for anyone else!
Ongoing project & please feel free to let me know if I've missed something 🌿
katcheung.com/psychedelic-et…
Katherine Cheung retweeted
‼️ New paper! MDMA "blue Mondays" & "suicide Tuesdays" are familiar phrases in recreational MDMA culture, describing low points in the days post-use. But do these aftereffects actually exist? Current research shows conflicting results. Thread👇
Katherine Cheung retweeted
doi.org/10.1007/s12152-026-0…
Beyond excited to announce this piece just published in @NeuroethicsJ!
During my research year at @JHPsychedelics, I had the privilege to co-facilitate prep, dosing and integration sessions for a number of participants in one of the psilocybin trials
"Participant experiences and recommendations for psychedelic clinical trials and future treatment delivery: a qualitative study with experts by experience from the Psychedelic Participant Advocacy Network"
frontiersin.org/journals/psy…
Katherine Cheung retweeted
New paper in JME Practical Bioethics: Katherine Cheung @Katherine_Chg, Edward Jacobs @eddietalksdrugs, and David Yaden @ExistWell review the ethics of psychedelic clinical trials and flag key concerns to resolve as psychedelics move toward real-world care.
jmepb.bmj.com/content/2/4/e0…
Katherine Cheung retweeted
Have you received psychedelic therapy through a legal pathway in Canada? 🇨🇦
We’re recruiting for a study in collaboration with the University of Ottawa @uOttawa.
Share your experience in a 15–25 min survey:
redcap.link/pace-ca
#PsychedelicResearch #LivedExperience
Katherine Cheung retweeted
A comprehensive review of bioethical progress and need for further work on psychedelic research and potential clinical applications across screening, informed consent, dosing, follow-up, & more. Work led by @Katherine_Chg w/ @eddietalksdrugs and me. Check out the thread and link:
A growing body of bioethical work has examined ethical issues related to the use of psychedelics in clinical research. With @eddietalksdrugs and @ExistWell, we try to take stock in our state-of-the-field review, published in JME Practical Bioethics.
A growing body of bioethical work has examined ethical issues related to the use of psychedelics in clinical research. With @eddietalksdrugs and @ExistWell, we try to take stock in our state-of-the-field review, published in JME Practical Bioethics.
While we have focused our review on the ethical challenges relevant to clinical trials, many of the considerations we discuss will remain relevant as psychedelics move towards clinical applications.
Open-access link: jmepb.bmj.com/content/2/4/e0…
Katherine Cheung retweeted
Meeting with scientists, clinicians, and bioethicists at @JHUBloombergCtr to discuss practical ethical guidelines for clinical applications of psychedelics. Meeting led by @eddietalksdrugs & @Katherine_Chg with @briandavidearp and I glad to see @psychedelethics doing applied work
Katherine Cheung retweeted
We are thrilled to share a major milestone for the Johns Hopkins Center for Psychedelic and Consciousness Research: @CeydaSayali, PhD, has received an R01 award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) — the first R01 awarded to an investigator at our Center.
The study will test a novel treatment approach for alcohol use disorder (AUD) combining psilocybin with personalized repetitive transcranial magnetic stimulation (rTMS). This is the first study to investigate this combination for AUD, with rTMS targets individualized using fMRI to identify each participant’s brain circuitry involved in regulating alcohol craving.
Using fMRI and TMS-EEG, the study will also examine how this combined intervention changes the neural mechanisms underlying craving, cognitive control, and treatment response.
By integrating psychedelic pharmacology, personalized brain stimulation, and multimodal neuroscience, this work aims to advance both treatment development and our understanding of how brain-based interventions can reduce problematic alcohol use.
Congratulations to Dr. Sayalı and the research team on this important achievement and exciting new direction for the Center.
Katherine Cheung retweeted
The first completely on-site preclinical animal study from @JHPsychedelics.
An immensely valuable collaboration with Division of Behavioral Biology. So grateful that I got to lead it and work with what can only be called the dream team!
Unroll the tweet below for deets đź“ś
New paper led by @PraachiTiwari, a former postdoc in @TheYadenLab, now faculty at Div of Behavioral Bio & @JHPsychedelics (also w/ @CassieMoorePhD, Brian Jenkins, Elise Weerts, me).
We examined how psilocybin affects a broader range of spontaneous behaviors in rats than HTR...
Katherine Cheung retweeted
New paper – Validating and Creating a Short-Form of the Persisting Effects Questionnaire: A Measure of Positive and Negative Outcomes from Psychedelic Experiences
The Persisting Effects Questionnaire (PEQ) is a measure of self-reported positive and negative effects from psychedelic experiences. While commonly used, the PEQ has never been formally validated, and is time-intensive and complex for both participants and researchers.
Using a multi-study approach, CPCR researchers created and validated the Persisting Effects Questionnaire – Short Form (PEQ-SF), a scale that is more easily understood and reduces burden for study teams and participants.
Read the paper here: journals.sagepub.com/doi/10.…
Katherine Cheung retweeted
Representing @TheYadenLab at @JHPsychedelics & @psychedelethics at @FDA. Postdoc Eddie Jacobs @eddietalksdrugs spoke to how the evidence on psychedelic treatments comes from clinical trials, so those safeguards should be used for initial roll-out, to be adjusted based on data…
Katherine Cheung retweeted
Psychedelic treatments are getting leaner as they approach licensing. Our (@IanRou of @PsyPANglobal, @HattiWells, and @drrosalindwatts) new Perspective in @TheCJPsych argues this gives us (more) reason to pay attention to patients’ social/relational environments🧵
Safety and Mental Health Outcomes of Oregon State-Regulated Psilocybin Services
jamanetwork.com/journals/jam…
Katherine Cheung retweeted
Great article in Scientific American on the Hopkins Post Psychedelic Difficulties Clinic!
As psychedelic therapies expand, new clinics treat uncommon long-term harms
spklr.io/6019ERHoz
"Context as Contraindication: Ethical Challenges of Psychedelics and Other Neuroplasticity-Enhancing Drugs"
link.springer.com/article/10…
